Anti-PD-L1 Boasts Benefit, Tolerability in Gastric Cancer

Dr Brandon Smaglo reports on 2 studies from 2015 GCIS, one showing benefit from pembrolizumab in gastric cancer, another suggesting that less palliative therapy may be warranted in esophageal cancer.

Source: Medscape Oncology - February 3, 2015 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts